Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants
Author: Collins, C.
Makrides, M.
McPhee, A.
Sullivan, T.
Davis, P.
Thio, M.
Simmer, K.
Rajadurai, V.
Travadi, J.
Berry, M.
Liley, H.
Opie, G.
Tan, K.
Lui, K.
Morris, S.
Stack, J.
Stark, M.
Chua, M.
Jayagobi, P.
Holberton, J.
et al.
Citation: New England Journal of Medicine, 2017; 376(13):1245-1255
Publisher: Massachusetts Medical Society
Issue Date: 2017
ISSN: 0028-4793
Statement of
Carmel T. Collins, Maria Makrides, Andrew J. McPhee, Thomas R. Sullivan, Peter G. Davis, Marta Thio, Karen Simmer, Victor S. Rajadurai, Javeed Travadi, Mary J. Berry, Helen G. Liley, Gillian F. Opie, Kenneth Tan, Kei Lui, Scott A. Morris, Jacqueline Stack, Michael J. Stark, Mei-Chien Chua, Pooja A. Jayagobi, James Holberton, Srinivas Bolisetty, Ian R. Callander, Deborah L. Harris and Robert A. Gibson
Abstract: Background: Studies in animals and in humans have suggested that docosahexaenoic acid (DHA), an n-3 long-chain polyunsaturated fatty acid, might reduce the risk of bronchopulmonary dysplasia, but appropriately designed trials are lacking. Methods: We randomly assigned 1273 infants born before 29 weeks of gestation (stratified according to sex, gestational age [<27 weeks or 27 to <29 weeks], and center) within 3 days after their first enteral feeding to receive either an enteral emulsion providing DHA at a dose of 60 mg per kilogram of body weight per day or a control (soy) emulsion without DHA until 36 weeks of postmenstrual age. The primary outcome was bronchopulmonary dysplasia, defined on a physiological basis (with the use of oxygen-saturation monitoring in selected infants), at 36 weeks of postmenstrual age or discharge home, whichever occurred first. Results: A total of 1205 infants survived to the primary outcome assessment. Of the 592 infants assigned to the DHA group, 291 (49.1% by multiple imputation) were classified as having physiological bronchopulmonary dysplasia, as compared with 269 (43.9%) of the 613 infants assigned to the control group (relative risk adjusted for randomization strata, 1.13; 95% confidence interval [CI], 1.02 to 1.25; P=0.02). The composite outcome of physiological bronchopulmonary dysplasia or death before 36 weeks of postmenstrual age occurred in 52.3% of the infants in the DHA group and in 46.4% of the infants in the control group (adjusted relative risk, 1.11; 95% CI, 1.00 to 1.23; P=0.045). There were no significant differences between the two groups in the rates of death or any other neonatal illnesses. Bronchopulmonary dysplasia based on a clinical definition occurred in 53.2% of the infants in the DHA group and in 49.7% of the infants in the control group (P=0.06). Conclusions Enteral DHA supplementation at a dose of 60 mg per kilogram per day did not result in a lower risk of physiological bronchopulmonary dysplasia than a control emulsion among preterm infants born before 29 weeks of gestation and may have resulted in a greater risk. (Funded by the Australian National Health and Medical Research Council and others; Australian New Zealand Clinical Trials Registry number, ACTRN12612000503820 .).
Keywords: Humans
Bronchopulmonary Dysplasia
Docosahexaenoic Acids
Regression Analysis
Double-Blind Method
Gestational Age
Infant, Newborn
Infant, Premature
Rights: Copyright © 2017 Massachusetts Medical Society. All rights reserved.
DOI: 10.1056/NEJMoa1611942
Grant ID:
Appears in Collections:Aurora harvest 3
Paediatrics publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.